10 leading companies forecast to suffer poor Q4 results

Ten major pharmaceutical firms are likely to see their fourth-quarter earnings rise a mere 4.2 percent on-year, buffeted by inevitable handling of drug inventories ahead of the massive drug price cuts starting April, Shinhan Investment and Securities said.

By contrast, Green Cross’s sales are expected to rise 26.4 percent to 191 billion won for the last quarter, while Dong-A is predicted to ...